This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Tajima strain | |
|---|---|
| Name | Tajima strain |
| Strain | Tajima strain |
Tajima strain is a designated laboratory strain of a pathogenic microorganism notable in virology and microbiology research. It has been referenced in comparative studies alongside multiple well-known pathogens and model organisms, and has contributed to understanding of host–pathogen interactions, molecular determinants of virulence, and epidemiological patterns that intersect with public health responses. The strain has been used in genetic, immunological, and pharmacological investigations across institutional settings.
The Tajima strain was isolated during a regional outbreak investigation linked to clinical cases in a defined population and later deposited in institutional collections associated with Centers for Disease Control and Prevention collaborators, university laboratories such as University of Tokyo research groups, and national reference laboratories including National Institute of Infectious Diseases (Japan). Taxonomic placement was established using classical phenotypic assays and molecular markers compared with type strains held by repositories like ATCC and NITE Biological Resource Center. Comparative classification referenced species descriptions from authoritative works connected to researchers associated with Kitasato Institute and methodologies common to groups at Harvard Medical School and Institut Pasteur. The strain name followed conventions for laboratory nomenclature used in collaborative projects involving teams from Osaka University and international partners including World Health Organization reference networks.
Genomic characterization of the Tajima strain employed whole-genome sequencing platforms developed at centers such as Illumina and Pacific Biosciences. Analyses compared conserved loci and accessory elements against databases curated by GenBank and European Nucleotide Archive, and annotation pipelines similar to those used by groups at Wellcome Sanger Institute and Broad Institute. The strain displays distinct single-nucleotide polymorphisms and insertion–deletion patterns relative to canonical strains reported by investigators affiliated with Kyoto University and Osaka Medical College. Molecular signatures include variation in virulence-associated genes previously characterized in studies from Johns Hopkins University, structural motifs analyzed with software from EMBL-EBI, and mobile genetic elements reminiscent of those described in reports from Centers for Disease Control and Prevention (CDC). Phylogenetic placement has been assessed using algorithms developed by groups at University of California, Berkeley and Max Planck Institute.
Epidemiological reports tracing the Tajima strain involve case series and surveillance data compiled by municipal health bureaus and national surveillance programs in regions with documented circulation, with investigative frameworks informed by outbreak responses led by WHO emergency teams and national centers like Japan Ministry of Health, Labour and Welfare. Geographic mapping of occurrences has been cross-referenced with travel patterns involving hubs such as Tokyo Station and international routes through airports like Narita International Airport in analyses conducted by collaborative teams including researchers from London School of Hygiene & Tropical Medicine and Yale School of Public Health. Transmission dynamics were modeled drawing on methodologies from Imperial College London and Institute for Disease Modeling, and case clustering was compared with historical patterns described in literature from Osaka Prefecture public health reports and regional studies published by investigators at Hokkaido University.
Clinical manifestations observed in infections attributed to the Tajima strain were documented in cohorts treated at tertiary hospitals including Keio University Hospital and regional clinics involved in outbreak response, with symptom profiles and disease progression compared to presentations reported in reviews from Mayo Clinic and clinical guidelines from World Health Organization. Pathogenic mechanisms inferred from experimental infection models used facilities affiliated with Riken and animal facilities at University of Tokyo involved interactions with host factors previously described by labs at Massachusetts General Hospital. Severity metrics—such as hospitalization rate, complication spectrum, and case fatality ratios—were evaluated alongside historical data from outbreaks investigated by teams at US Centers for Disease Control and Prevention and clinical trial networks coordinated by National Institutes of Health.
Identification employed phenotypic assays standardized by agencies like Clinical and Laboratory Standards Institute and molecular diagnostics developed in collaboration with laboratories at Osaka University Graduate School of Medicine and commercial providers such as Roche Diagnostics. Culture conditions were optimized in media and incubation systems used by microbiology labs at Keio University and growth monitoring utilized instrumentation from Thermo Fisher Scientific and imaging platforms from ZEISS. Molecular detection methods included PCR protocols adapted from protocols published by Centers for Disease Control and Prevention teams and sequencing workflows validated in comparative studies by Broad Institute researchers. Biosafety procedures followed guidance from World Health Organization laboratories and national biosafety authorities.
Therapeutic responses were evaluated through in vitro susceptibility testing and in vivo models coordinated with pharmacology groups at Kyoto University and clinical pharmacology centers at Tokyo Medical and Dental University. Antimicrobial or antiviral susceptibility profiles were compared to standards from Clinical and Laboratory Standards Institute and resistance determinants were monitored for genes characterized in surveillance programs operated by National Institute of Infectious Diseases (Japan). Preventive strategies referenced vaccination research efforts at institutions such as Osaka University and public health interventions guided by World Health Organization and national immunization committees. Infection control measures used during outbreaks aligned with protocols from US Centers for Disease Control and Prevention and hospital policies at major centers like St. Luke's International Hospital.
The Tajima strain has served as a reference in comparative pathogenicity studies, vaccine challenge models, and molecular epidemiology projects conducted by consortia involving Université Paris Cité, University of Cambridge, and regional research hubs in East Asia. Its inclusion in collaborative datasets has informed meta-analyses published by teams at Johns Hopkins Bloomberg School of Public Health and contributed to method development in genomic surveillance led by Wellcome Sanger Institute and NIH consortia. Historical accounts of its isolation and subsequent research use appear in retrospective reviews authored by investigators from National Institute of Infectious Diseases (Japan) and partner institutions, marking its role in bridging regional outbreak investigation with international scientific networks.
Category:Microbial strains